SIMPLIFIED DOSING AND MONITORING OF VANCOMYCIN FOR THE BURN CARE CLINICIAN

被引:17
作者
RICE, TL
机构
[1] The University of Michigan College of Pharmacy, The University of Michigan Hospitals and Clinics, Ann Arbor, MI
关键词
D O I
10.1016/0305-4179(92)90032-P
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Vancomycin has excellent activity against Gram-positive bacteria and is often selected for use in the infected burn patient. Because of multiple-compartment pharmacokinetics, vancomycin serum concentrations can decrease dramatically in a short time period following the end of an intravenous infusion. This accounts for the widely divergent recommendations for serum vancomycin peak concentrations, e.g. from 15 mg/l up to 80 mg/l, when the time for blood sampling following the end of intravenous infusion is different. It is in general not necessary to monitor vancomycin peak concentrations, not only because its toxic potential is overrated but also because potential toxicity and therapeutic efficacy are correlated with trough concentrations. Post-distribution 'peak' concentrations are generally only useful for determining the optimal dosing interval for patients with impaired renal function. A dosing and monitoring paradigm for vancomycin therapy in burned adults has been devised for burn care clinicians. It provides suggested dose and dosing intervals based on body weight and creatinine clearance, with specific recommendations for regimen modification based upon the results of trough serum concentration determinations.
引用
收藏
页码:355 / 361
页数:7
相关论文
共 54 条
[1]  
Ackerman, Taylor, Olsen, Et al., Vancomycin serum protein binding determination by ultra-filtration, DICPAnn. Pharmacother., 22, (1988)
[2]  
Anne, Hu, Chan, Et al., Potential problem with fluorescence polarization immunoassay cross-reactivity to vancomycin degradation product CDP-1: its detection in sera of renally impaired patients, Ther. Drug Monit., 11, (1989)
[3]  
Bailie, Neal, Vancomycin ototoxicity and nephrotoxicity, A review, 3, (1988)
[4]  
Bellomo, Emest, Parkin, Clearance of vancomycin during continuous arteriovenous hemodiafiltration, Crit. Care Med., 18, (1990)
[5]  
Blevins, Halstenson, Salem, Et al., Pharmacokinetics of vancomycin in patients undergoing continuous ambulatory peritoneal dialysis, Antimicrob. Agents Chemother., 25, (1984)
[6]  
Blouin, Bauer, Miller, Et al., Vancomycin pharmacokinetics in normal and morbidly obese subjects, Antimicrob. Agents Chemother., 21, (1982)
[7]  
Boeckh, Lode, Bomer, Et al., Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers, Antimicrob. Agents Chemother., 32, (1988)
[8]  
Brater, Bawdon, Anderson, Et al., Vancomycin elimination in patients with bum injury, Clin. Pharmacol. Ther., 39, (1986)
[9]  
Brown, Altmann, Cunningham, Et al., Pharmacokinetics of once daily intra-peritoneal aztreonam and vancomycin in the treatment of CAPD peritonitis, J. Antimicrob. Chemother., 25, (1990)
[10]  
Brown, Ho, Fong, Et al., Effects of hepatic function on vancomycin clinical pharmacology, Antimicrob. Agents Chemother., 23, (1983)